Geneva, Switzerland and Boston, MA -May 31, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Month: May 2018
ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor
Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, Guillaume P, Lluel P, Meen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.
Q1 Report 2018
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results…
Q1 2018 ObsEva SA Earnings Conference Call
ObsEva Annual General Meeting 2018
Wednesday, May 9, 2018 Location: Geneva Supporting Materials:
ObsEva Annual General Meeting 2018
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
Geneva, Switzerland and Boston, MA – May 8, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…